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Objectives The aim of this study was to close ventricular septal defects (VSDs) directly through the
chest wall using magnetic resonance imaging (MRI) guidance, without cardiopulmonary bypass, ster-
notomy, or radiation exposure.
Background Surgical, percutaneous, and hybrid management of VSD each have limitations and
nown morbidity.
ethods Percutaneous muscular VSDs were created in 10 naive Yorkshire swine using a transjugu-
ar laser catheter. Under real-time MRI guidance, a direct transthoracic vascular access sheath was
ntroduced through the chest into the heart along a trajectory suitable for VSD access and closure.
hrough this transthoracic sheath, muscular VSDs were occluded using a commercial nitinol device.
inally, the right ventricular free wall was closed using a commercial collagen plug intended for ar-
erial closure.
esults Anterior, posterior, and mid-muscular VSDs (6.8  1.8 mm) were created. VSDs were closed
successfully in all animals. The transthoracic access sheath was displaced in 2, both fatal. Thereafter,
we tested an intracameral retention sheath to prevent this complication. Right ventricular access
ports were closed successfully in all, and after as many as 30 days, healed successfully.
Conclusions Real-time MRI guidance allowed closed-chest transthoracic perventricular muscular
VSD closure in a clinically meaningful animal model. Once applied to patients, this approach
may avoid traditional surgical, percutaneous, or open-chest transcatheter (“hybrid”)
risks. (J Am Coll Cardiol Intv 2011;4:1326–34) © 2011 by the American College of Cardiology
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1327Ventricular septal defects (VSDs) represent the most common
congenital heart abnormalities managed in childhood and are
also common in adults (1). Traditional surgical VSD repair
requires sternotomy, cardiopulmonary bypass, and blood prod-
ucts. Right ventricular trabeculation or apical position can
make these defects difficult to locate and close completely.
After surgical repair, one-quarter have persistent, residual
lesions (2). In some settings (i.e., post-infarction, iatrogenic, or
post-traumatic VSDs), surgery may be unattractive.
Percutaneous catheter-based VSD closure, an alternative
to surgery, suffers from radiation exposure and limited
visualization, even with adjunctive echocardiography. Fur-
thermore, children may have prohibitively small access
vessels or may suffer hemodynamic compromise (3) during
transcatheter attempts. Hybrid (open-chest transcatheter)
procedures aim to address these limitations, at the expense
of surgical morbidity.
Real-time magnetic resonance imaging (MRI) guid-
ance might overcome the deficiencies of surgical, percu-
taneous, and hybrid approaches by affording surgical type
exposure without surgical risk (4). We hypothesized that
muscular VSDs could be repaired with little morbidity using
closed-chest transthoracic MRI-guided techniques.
Methods
Animal Procedures
Animal procedures were approved by the National Heart,
Lung, and Blood institutional animal care and use commit-
tee. Nineteen naive Yorkshire swine (Archer Farms, Dar-
lington, Maryland; 46.5  10.1 kg) were anesthetized and
echanically ventilated. Percutaneous arterial, venous, and
ubxiphoid pericardial access was obtained. Experiments
ere conducted in a combined interventional cardiovascular
RI and x-ray fluoroscopy suite (1.5-T Espree, Axiom
rtis; Siemens, Erlangen, Germany) (4). Heparin main-
ained activated clotting times 250 s.
Percutaneous Animal Model of Muscular VSD
Using an Excimer Laser Sheath
Muscular VSD was created using coregistered x-ray and MRI
roadmaps (5) (x-ray fused with MRI [XFM]) (Figs. 1A to 1C).
he target was punctured using a standard 18-ga transseptal
eedle (Brockenbrough, Medtronic, Minneapolis, Minne-
ota) (Figs. 1A and 1B). An 0.018-in guidewire (V-18,
oston Scientific, Natick, Massachusetts) was delivered to
he left ventricle. It was snared using a catheter passed
etrograde across the aortic valve. The wire was exteriorized
hrough the femoral arterial sheath creating an “arterio-
enous loop.” A 16-F excimer laser catheter intended to
xtract pacemaker leads (SLS-II, Spectranetics, Colorado
prings, Colorado) was activated in multiple passes over the
uidewire to create a muscular VSD (Fig. 1C). The defect Mize was measured using radiocontrast angiography and by
RI (Fig. 1D). The degree of left to right shunt was
easured by Fick oximetry and by velocity-encoded MRI.
Magnetic Resonance Imaging
Steady-state free precession (SSFP) imaging followed usual
parameters: repetition time (TR)/echo time (TE), 3.2/1.5
ms; flip angle, 80°; bandwidth, 930 Hz/pixel; field of view
(FOV), 340  276 mm; matrix, 192  156 pixels; slice
thickness, 6 mm. Typical “black-blood” turbo spin echo
images used TR/TE, 700/34 ms; flip angle, 180°; band-
width, 292 Hz/pixel; FOV, 340  276 mm; matrix, 256 
125 pixels; slice thickness, 6 mm. Typical velocity-encoded
gradient echo acquisition parameters were TR/TE, 12.8/2.9
ms; flip angle, 30°; bandwidth, 434 Hz/pixel; FOV, 370 
220 mm; matrix, 256  88 pixels; slice thickness, 6 mm,
yquist limit, 100 to 125 cm/s.
VSD dimensions were measured during systole on repre-
entative short-axis or long-axis
SFP images, and the largest di-
ension was chosen for device
izing.
Real-time MRI for interven-
ional procedures used SSFP
ith TR/TE, 2.8/1.4 ms; flip
ngle, 60°; bandwidth, 800 Hz/
ixel; matrix, 192  108; and
OV, 32  24 cm.
“Active” MRI Catheter Devices
Interventional devices were visual-
ized as “active” antennae incorpo-
rating MRI receiver coils. We
have found these more conspicu-
ous than “passive” devices that are visualized based on intrinsic
materials properties (4).
To provide clear delineation of the needle tip and shaft
location during access, we used an actively visualized needle.
An MRI needle incorporated an elongated loop coil and
multiple tight windings to enhance visibility (Figs. 2 and 3) (6).
“Passive” hydrophilic coated nitinol guidewires (Terumo,
omerset, New Jersey) were used for wire exchange. VSD
ere crossed with a loop-less-design, “active” 0.035-in
uidewire (Fig. 3) (7).
The marketed occluder device (Amplatzer Muscular
SD Occluder, AGA Medical, Plymouth, Minnesota)
ncorporates a stainless-steel microscrew hub to mate with a
elivery cable. To avoid large MRI artifacts, the steel
icroscrew hub was replaced (courtesy of AGA Medical)
ith a custom titanium microscrew on 8-mm occluders.
We developed an active MRI delivery cable to enhance
isibility of the modified VSD occluder during real-time
Abbreviations
and Acronyms
FOV  field of view
MRI  magnetic resonance
imaging
RV  right ventricle
SSFP  steady-state free
precession
TE  echo time
TR  repetition time
VSD  ventricular septal
defect
XFM  x-ray fused with
magnetic resonance imagingRI (Fig. 3). A mating titanium microscrew was laser
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1328welded to the active MRI delivery cable tip (7). The
oop-less-design cable was tuned and matched with the
mplant to change cable signal during sequential disk
xpansion and upon release.
MRI-Guided Procedure
Closed-chest transthoracic MRI-guided cardiac access. Real-
time SSFP MRI guided all procedural steps. Two orthog-
onal (short- and long-axis) slices were selected to represent
the VSD to the operator along a desired trajectory, with
simultaneous volume-rendering of the slices in their
3-dimensional position (Fig. 2).
A large field of view allowed extrathoracic maneuvers to be
viewed interactively. First, a trajectory was planned by selecting
a skin entry site and a predicted right ventricular entry site
Figure 1. Percutaneous Muscular VSDs Created Under XFM Guidance
(A and B) X-ray fused with magnetic resonance imaging (XFM) image shows i
views. XFM road map includes right (yellow) and left (blue) ventricular endoc
XFM image shows laser sheath extraction catheter (white arrow) during musc
“bright blood” image depicts muscular VSD (black arrow).intended to facilitate later crossing of the ventricular septal fdefect. Next, the active needle was introduced through the skin
and chest wall into the right ventricle (RV) and exchanged over
a passive nitinol guidewire for a passive 9-F introducer sheath.
Sheath position was confirmed using 5 ml (1%) gadopentetate-
dimeglumine injection (Magnevist, Bayer, Wayne, New Jersey)
during real-time saturation-prepared MRI.
Transthoracic MRI-guided muscular VSD closure. With a
ransthoracic right ventricular introducer sheath in place,
he operator manipulated the active guidewire across the
uscular VSD into the left ventricle. Over this wire, the
ntroducer sheath was delivered into the left ventricle and
ts position confirmed with a hand injection of dilute
adopentetate. The modified 8-mm AGA muscular VSD
ccluder device—mounted on the active delivery cable—
as then delivered to the muscular VSD in standard
ocedure needle (white arrow) and target (red outline) in 2 orthogonal
contours, left ventricular epicardial contour (green), and aortic root (red). (C)
entricular septal defect (VSD) creation. (D) Steady-state free precession (SSFP)ntrapr
ardial
ular vashion (3) (Fig. 3).
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1329Transthoracic MRI-guided RV free wall closure. An off-the-
helf 8-F absorbable collagen vascular closure device
Angio-Seal VIP, St. Jude Medical, Minnetonka, Minne-
ota) was used to close the RV free wall under real-time
RI (Fig. 4) (8). We created “permissive pericardial tampon-
de” by instilling saline through the pre-positioned pericardial
rain to separate the visceral and parietal pericardium and
ssure delivery of the external collagen to the epicardial surface.
fterwards, the pericardial fluid was evacuated.
Experimental Design and Data Analysis
Once the animal model was developed, we attempted to
close the VSD in 2 nonsurvival animals and then in 8
animals to survive 2 days or 1 month. We performed
interval imaging and catheterization followed by necropsy
and histopathology.
Blood was tested using bedside human assays for chem-
istry (i-Stat, Abbott, Princeton, New Jersey), oximetry
(Avox, San Antonio, Texas), and coagulation (Hemachron,
ITC, Edison, New Jersey).
Effusions were measured by maximal dimension in mul-
tiplanar MRI. RV sheath placement time began when the
active needle was placed on the chest wall until placement
was confirmed with selective gadopentetate injection. VSD
crossing time was from the active wire insertion until LV
sheath placement was confirmed with selective gadopen-
tetate injection. Occluder deployment time started with the
introduction of the delivery system and ended with device
release. RV free wall closure started with positioning the
vascular sheath in RV and ended with aspiration of pericar-
Figure 2. Real-time MRI Imaging Display During Closed-Chest
Transthoracic Needle Access Targeting Muscular VSD
Three-dimensional rendering of real-time SSFP imaging slice (short axis)
and “black-blood” road map (long axis) displays active needle (green) tar-
geting mid-muscular VSD (white arrow) (Online Video 1). Abbreviations as
in Figure 1.dial fluid after vascular closure device deployment. Totalprocedural time was defined by the start of RV sheath
placement time and conclusion of RV free wall closure.
Results are expressed as mean  SD.
Results
Animal model. We attempted to create a muscular VSD in
9 animals, and failed in 2 because of cardiac perforation or
efractory ventricular fibrillation. In the first 2 animals with
uccessful muscular VSD creation, closure was not at-
empted. In 5 animals, the resulting VSD was too large, and
nimals suffered acute heart failure before the lesion could
e treated.
We attempted VSD closure in the 10 remaining animals
n 3 phases: nonsurvival initial feasibility (n  2), survival
or 2 days (n  4), and survival for 30 days (n  4). The
aximum VSD dimension was 6.8  1.8 mm by radiocon-
rast angiography and 5.1 0.8 by SSFP MRI. The defects
ere located in the following septal locations: anterior (n 
), posterior (n 5), and midmuscular (n 3). Intracardiac
hunts (pulmonary vs. systemic blood flow or Qp/Qs) were
ild (1.1  0.3 by Fick technique, 1.2  0.2 by velocity-
ncoded MRI). Creating the defect model also led to small
cute pleural and pericardial effusions (Table 1).
Transthoracic cardiac access. Real-time MRI successfully
guided active needle access, wire exchange, and delivery of
9-F introducer sheaths into the RV in all animals. Multiple
interactive imaging planes allowed selection of an optimal
needle trajectory (Fig. 2, Online Video 1). RV sheath
placement required 8.5  5.3 min. This was not associated
with sustained arrhythmia or hemodynamic change.
Transthoracic MRI-guided muscular VSD closure. Muscular
VSD device closure was achieved in all animals (n  10)
(Fig. 3, Online Video 2). Real-time MRI guided post-
deployment positioning to avoid critical structures, such as
atrioventricular valves. Procedural times for each step were
VSD crossing time (10.2 13.7 min), occluder deployment
time (7.8  5.7 min). Activated clotting times were 407 
205 s. Animals were hemodynamically stable, with no
sustained arrhythmias documented.
In 1 animal, real-time MRI demonstrated inadvertent
entrapment of a mitral subvalvar element (Online Video 3),
and guided repositioning.
Transthoracic MRI-guided RV free wall closure. Right ven-
tricular free wall closure, when attempted, was successful in
all animals (n  6; 6.2  6.5 min). Permissive pericardial
amponade entailed temporary instillation of normal saline
150  42.4 ml) to facilitate appropriate delivery and
eployment of the collagen sponge, followed by withdrawal
f serosanguinous fluid (155  35.4 ml) (Fig. 4, Online
Video 4).
The total procedure time, from initial needle access tofinal RV closure, was 77.2  27.4 min.
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1330Complications and mitigation approach. Two animals died
despite successful VSD closure as complications of “lost”
access to the right ventricular cavity before an attempt at
nonsurgical access port closure, 1 each intended for 2- and
for 30-day survival, respectively.
We observed that inadvertent sheath withdrawal from
the small right ventricular cavity was related to sheath
retraction to expose and deploy the right ventricular disk
of the closure device, exacerbated by respiratory and
cardiac motion.
We sought a device to secure the sheath into the RV,
especially during deployment of the right ventricular disk.
We found a commercial balloon-tipped right ventricular
intracameral retention sheath (IABC, Cook Medical,
Bloomington, Indiana) to be suitable to prove the concept
(Fig. 5). This afforded reliable right ventricular intracameral
access, as well as effective pericardial layer separation during
permissive pericardial tamponade.
Procedural and post-intervention surveillance. In follow-
p, no animal showed evidence of coronary artery injury
anifest as electrocardiographic injury current or wall
Figure 3. Real-Time MRI Guidance of Muscular VSD Occluder Delivery
(A) “Active” needle (green) puncture through the chest wall and the right ven
(B) “Active” guidewire (red signal) is used for crossing VSD. (C) Dilute gadolin
occluder device is mounted on “active” delivery cable (green) and delivered t
right ventricular disk (white arrow) is deployed. “Active” delivery cable (green
the device is released (Online Videos 2 and 3). Dilute gadolinium highlights thotion abnormality. No coronary ischemia occurred.ne animal experienced transient heart block after device
mplantation that self-resolved. No significant atrioven-
ricular valve regurgitation was detected early or in
ollow-up.
Follow-up data are presented in Table 1. No significant
esidual muscular VSD shunt was detected after occluder
elease. Follow-up imaging showed good occluder position
Fig. 6). Two animals in the 1-month survival group had
mall pericardial effusions (hemodynamically insignificant)
rained after surveillance MRI (2 days post-intervention).
ericardial effusions did not recur.
Necropsy and histopathology. Gross pathology revealed ap-
propriate placement and endothelization of the VSD oc-
cluder device (Fig. 7). No atrioventricular or semilunar valve
apparatus was entrapped by the device. In swine surviving
for 2 days, components of the vascular closure device were
visible and found in the expected position. One animal had
the collagen plug deployed outside the pericardium. In
animals surviving for 1 month, the collagen plug had
resorbed and was no longer identifiable on epicardial sur-
face. Partial remnants of the copolymer anchor were visu-
r free wall into the right ventricular cavity, avoiding septal injury/puncture.
jection conﬁrms left ventricle (LV) sheath placement. (D) Modiﬁed VSD
defect. First, the left ventricular disk (white arrow) is deployed. (E) Next, the
ned such that signal attenuation occurs with full device delivery. (F) Finally,
ss sheath (white arrow). Abbreviations as in Figure 1.tricula
ium in
o the
) is tu
e accealized on the endocardial surface.
ne Vid
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1331Histopathology survey (hematoxylin and eosin stain) com-
pared the right ventricular free wall at the closure site and distal
to closure site. The epicardial surface was similarly mildly
fibrotic at both sites. In contrast to the distal site, inflammatory
changes at the closure site were noted in a predominately
subendocardial location. Fibrosis (highlighted by trichrome
stain), edema, lymphocytic infiltrate, and foreign body giant
cell reaction were limited to this immediate location (Fig. 7).
Figure 4. Right Ventricular Free Wall Closure Performed With Vascular Clo
(A) Muscular ventricular septal defect closure device (white arrow) in good p
injection of dilute gadolinium. (C) Saline injected into pericardium (white arro
pulled against right ventricular endomyocardial wall (white arrow). (E) Collag
through access sheath. (F) Evacuation of pericardial space (white arrow) (Onli
Table 1. Procedural Details
Baseline (mm)
(n  8)
Post-muscular VSD Creation
(n  8)
Hemoglobin, g/dl 7.5 0.7 7.2 0.5
Hematocrit, % 22.0 2.1 21.1 1.6
Mean systemic blood
pressure, mm Hg
60.1 12.6 54.9 9.6
Pericardial effusion, mm NA 3.2 3.0
Left pleural effusion, mm NA 0.3 0.9
Right pleural effusion, mm NA 1.7 1.7
Fick oximetry shunt
quantiﬁcation, Qp/Qs
0.9 0.1 1.1 0.3
Phase-contrast shunt
quantiﬁcation, Qp/Qs
1.0 0.0 1.2 0.2Values are mean SD. NA not applicable; Qp/Qs pulmonary to systemic blood flow ratio; VSD ventDiscussion
We showed direct transthoracic VSD repair to be feasible
under real-time MRI guidance. MRI depicted the defect,
the heart surface, and the chest wall in relation to each other
for planning and execution of needle, guidewire, and cath-
eter traversals into both right and left ventricular cavities.
Real-time MRI also provided straightforward visualization
evice Using Permissive Pericardial Tamponade Technique
. (B) Transthoracic access sheath (white arrow) position is conﬁrmed with
) Bioabsorbable co-polymer anchor is deployed through access sheath and
g is deployed on epicardial surface and tamped in place (white arrow)
eo 4).
Follow-Up
1 h (n  7) 2 Days (n  3) 2 Weeks (n  3) 1 Month (n  3)
8.1 1.9 8.1 0.5 NA 9.0 0.4
23.8 5.4 23.7 1.5 NA 26.7 1.2
49.8 9.4 59.7 4.7 NA 68.0 2.6
2.7 2.8 7.0 4.2 1.8 3.2 0.0 0.0
1.0 1.8 0.0 0.0 0.0 0.0 0.9 1.5
6.6 3.7 6.3 8.0 0.9 1.5 4.5 3.0
0.9 0.1 0.8 0.1 NA 1.0 0.1
0.9 0.0 1.0 0.0 1.0 0.0 1.0 0.0sure D
osition
w). (D
en pluricular septal defect.
icardia
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1332of all steps of closure: device delivery, deployment, and
release. Equally important, real-time MRI depicted struc-
tures in context in a way we find qualitatively superior to
x-ray and ultrasound guidance of conventional nonsurgical
structural heart procedures, because the heart, thorax,
pleura, and pericardium are displayed instantaneously
throughout.
Our closed-chest real-time MRI-guided transthoracic
VSD repair approach offers an alternative for small
children in whom percutaneous options are not possible
(vascular access) or pose unnecessary risk of major adverse
Figure 5. Right Ventricular Access Sheath With Balloon Locking Mechanis
(A) One potential “secure” transthoracic sheath (IABC, Cook Medical, Blooming
4-chamber views showing transthoracic access sheath with balloon (white arr
ing transthoracic access sheath with balloon tip (white arrow) inﬂated for peroutcomes (arrhythmia, hemodynamic compromise, car- odiac perforation, tamponade, death) (3). It may avert
cardiopulmonary bypass required in traditional VSD
surgical repair or sternotomy required even in hybrid
perventricular approaches.
In this preclinical experience with single “intentional”
defects, all VSD closure procedures were successful. We did
not encounter known complications of traditional (percuta-
neous, hybrid) VSD device closure, such as device emboli-
zation, residual shunt, atrioventricular valve distortion, ven-
tricular dysfunction, or left ventricular free wall damage
(2,9–11). Nor did we observe damage to coronary, pleural,
diana). (B) Close-up shows the balloon inﬂated. (C and D) Short-axis and
ﬂated in the right ventricle. (E and F) Short-axis and 4-chamber views show-
l separation during right ventricular free wall closure.m
ton, In
ow) inr intercostal arteries during percutaneous access (12).
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1333Even in this preliminary experience, procedure planning
and conduct was completed in a little more than 1 h. This
compares favorably with hybrid surgical (11,13) and percu-
taneous (2,10) approaches.
The marketed AGA medical VSD occluder and its
matching delivery cable each have a small stainless steel
Figure 6. MRI Demonstrating Successful Device Deployment and Right
Ventricular Free Wall Closure at 1-Month Follow-Up
SSFP “bright blood” image shows muscular VSD closure device (black arrow)
in good position. Abbreviations as in Figure 1.
Figure 7. Right Ventricular Free Wall: Gross Pathology and Histopathology
(A) Vascular closure device (collagen plug is visible; white arrow) deployed on
ble; white arrow) deployed on endocardial surface at 2 days. (C) Vascular clos
defect occluder (white arrow) visible from right ventricle. (E) Hematoxylin and
1 month shows foci of mature granulation tissue and foreign body giant cell r
percutaneous entry and closure site at 1 month.microscrew hub that distorts MR images. In collaboration
with the manufacturer, the microscrews were replaced with
titanium to eliminate the steel susceptibility artifact.
We further customized the delivery cable as an active
antenna device tuned to couple with the nitinol occluder in
the partially and fully deployed positions. This novel ap-
proach to deliberate coupling significantly enhanced visibil-
ity and performance of the device.
We were able to close 9-F access port holes in the RV
using a commercial vascular closure device, as has been
described in case reports (14). Our “permissive pericardial
tamponade” technique facilitated appropriate deployment of
the collagen sponge on the epicardial surface (8), but failed
without sequelae in 1 case. Two animals had small pericar-
dial effusions, which we drained on day 2 and which did not
recur. Similar pericardial collections are noted after “hybrid”
VSD closure (11). Gross pathology and histology at 1
month showed excellent healing of the access site and
resorption of the copolymer anchor. By contrast, we have
found this same collagen-based closure device to be unsuit-
able for closure of left ventricular access ports, and many
operators report serious consequences of simple sheath
withdrawal without surgical or device closure after transapi-
cal puncture for interventional procedures (15). Custom
epicardial closure solutions are under development using
sutures, staples, and other approaches.
The chief procedural limitation in our experience was
inadvertent loss of right ventricular access after VSD device
delivery, which proved lethal in 2 animals. We found an
alternative sheath solution that promises to mitigate this
limitation, by providing a secure “lock” of the sheath tip
rdial surface at 2 days. (B) Vascular closure device (copolymer anchor is visi-
vice (white arrow) on endocardial surface at 1 month. (D) ventricular septal
stain of right ventricular free wall at percutaneous entry and closure site at
n. (F) Trichrome stain (collagen colored blue) of right ventricular free wall atepica
ure de
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1334inside the right ventricle when necessary. In addition, it can
help to separate visceral and parietal pericardium during
access port closure. Lower-profile intracameral retention
sheaths are feasible.
The early nonrecurrent pericardial bleeding we experi-
enced might be less important in clinical practice, where
mitigation options include blood transfusion, reversal of
anticoagulation (intentionally avoided in these experiments
to “stress” hemostasis), temporary post-procedure pericar-
dial drain catheters, and surgical repair if indicated.
We created a new animal model of VSD using percutaneous
catheter techniques and MRI–x-ray co-registration. We had
been unsuccessful using echocardiographic guidance because of
poor acoustic windows. Before debulking myocardium using
the excimer laser sheath extraction catheter, we had been
unsuccessful in creating a sustained ventricular communication
even using large conventional (up to 18 mm) or cutting (up to
6 mm) angioplasty balloons. Nevertheless, these naive animals
suffered acute hemodynamic instability, accounting for signif-
icant procedural mortality during model creation. The acute
physiology in this model resembled post-infarction, traumatic,
and iatrogenic lesions. Our animal model challenged us to
target, cross, and close small defects compared with technically
easier larger chronic defects, in the range reported for hybrid
(11) and percutaneous (2,10) closure. That said, we were not
ble to create apical VSD.
We showed that a real-time MRI-guided direct trans-
horacic procedure is feasible. Clinical translation would
equire further development of the titanium microscrews,
ssurance of no heating during MRI, and adjunctive cath-
ter tools, such as an enhanced-conspicuity delivery sheath
nd “buddy” guidewires to enhance procedure safety.
Our transthoracic approach may be suitable for membra-
ous (16) and less common subarterial VSDs (13). Related
pplications for complex congenital interventions include
ransventricular atretic pulmonary valve perforation and
ransatrial septal perforation/septostomy. With suitable de-
ices, real-time MRI could facilitate percutaneous VSD
epair in larger children.
onclusions
Real-time MRI guided successful closed-chest transthoracic
muscular VSD closure in a swine model. This approach may
avoid traditional surgical, percutaneous, or open-chest
transcatheter (“hybrid”) risks. In the future, it may facilitate
or enhance a range of transatrial, transventricular, and
intrapericardial structural and electrophysiology cardiac
interventions.
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